Categories: News

Harrow Health to Announce Fourth Quarter and Year-End 2020 Financial Results on March 8, 2021

NASHVILLE, Tenn., Feb. 25, 2021 (GLOBE NEWSWIRE) — Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2020, on Monday, March 8, 2021, after the Nasdaq market close. The Company will also post its fourth quarter Letter to Shareholders to the “Investors” section of its website, harrowinc.com. Harrow Health will host a conference call and live webcast at 4:45 p.m. Eastern time to discuss the results and provide a business update.

Conference Call Details:  
Date: Monday, March 8, 2021
Time: 4:45 p.m. Eastern time
Participant Dial-in: (888) 506-0062 (U.S.)
(973) 528-0011 (International)
Replay Dial-in (Passcode 39840):
(telephonic replay through April 8, 2021)
(877) 481-4010 (U.S.)
(919) 882-2331 (International)
Webcast:
(online replay through June 8, 2021)
harrowinc.com

About Harrow Health
Harrow Health, Inc. (NASDAQ: HROW) is an ophthalmic-focused healthcare company. The Company owns ImprimisRx, the nation’s leading ophthalmology outsourcing and pharmaceutical compounding business, which was founded in 2014. Harrow Health also holds large equity positions in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals, all of which started as Harrow Health subsidiaries. Harrow Health also owns royalty rights in four clinical-stage drug candidates being developed by Surface Ophthalmics and Melt Pharmaceuticals. For more information about Harrow Health, please visit the Investors section of the corporate website, harrowinc.com.

Contact:
Jamie Webb, Director of Communications and Investor Relations
jwebb@harrowinc.com
615-733-4737

 

Staff

Recent Posts

AAMI Foundation Launches Michael Scholla Packaging Engineering Scholarship Fund

Calls for Contributions to Support Future Medical Device & Pharmaceutical Packaging LeadersArlington, Virginia--(Newsfile Corp. -…

50 minutes ago

Hemostemix Inc. Announces FDA Pre-IND Meeting and NBPP of $960,000

Calgary, Alberta--(Newsfile Corp. - December 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE:…

2 hours ago

Joe Albe, Ph.D., joins Washington Research Foundation as manager of grants and venture research

Albe brings extensive immunology and translational research experience to his full-time role working with WRF's…

2 hours ago

Omega Healthcare Named a Leader in the 2025-2026 IDC MarketScape for U.S. Revenue Cycle Management Service Solutions

BOCA RATON, Fla., Dec. 10, 2025 /PRNewswire/ -- Omega Healthcare, a leading provider of technology-driven healthcare…

2 hours ago

Homecare Homebase Shares Insights from CMS CY 2026 Home Health Final Rule Updates and Ongoing Advocacy Efforts

Industry collaboration leads to significant improvements in CY 2026 Final Rule but long-term stability remains…

2 hours ago

PatientRightsAdvocate.org Launches Ohio Hospital Price Finder Tool

Ohio patients empowered to compare prices, save on care, fight surprise bills COLUMBUS, Ohio,, Dec. 10,…

2 hours ago